FORM 4

## UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL									
OMB Number:	3235-0287								
Fatimated average I	hurdon								

0.5

hours per response:

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>Cearnal Martin E</u>					CU	2. Issuer Name <b>and</b> Ticker or Trading Symbol CUMBERLAND PHARMACEUTICALS										5. Relationship of Reporting Person(s) to Issuer (Check all applicable)						
					IN	INC [ CPIX ]									X Directo			10% Owner				
(Last)	(F	irst) (	Middle)											_	X	belov	er (give title v)		below)	(specify		
2525 WEST END AVE.						3. Date of Earliest Transaction (Month/Day/Year)										Sr VP/Chief Commercial Officer				icer		
SUITE 950				04/0	04/07/2017																	
					4. If	4. If Amendment, Date of Original Filed (Month/Day/Year)									6. Individual or Joint/Group Filing (Check Applicable							
(Street)									Ü		•	•	,		.ine)		·					
NASHVI	LLE T	<b>N</b> 3	37203												X		n filed by One					
																Form Pers	n filed by Mor on	e than (	One Rep	orting		
(City)	(5	tate) (	Zip)																			
	Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned																					
1. Title of Security (Instr. 3)  2. Transac Date (Month/Da					Execution Date,		3. Transaction Disposed Of (D) (Instr. 3, 0) 8)					4 and Secu Bene		cially d Following	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)		7. Nature of Indirect Beneficial Ownership					
									Code	v	Amount		(A) or (D)	Price	Tra		action(s) 3 and 4)			(Instr. 4)		
Common Stock 04/07/2					//2017	2017		A		11,600(1)		A	\$6.45		142,516		I	D				
Common Stock 04/0				04/07	2017			F		1,959(2)		D	\$6.45		140,557		I	D				
	Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)																					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date if any (Month/Day/Yea		4. Transaction Code (Instr. 8)		n of		6. Date E Expiratio (Month/D	e	7. Title and Amount of Securities Underlying Derivative Security (Instr. and 4)				ivative urity tr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s (Instr. 4)	Ow For Dire or I (I) (	Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)			
			Code	v	(A)	(D)	Date Exercisa		Expiration Date	Title	of	nber res										

## Explanation of Responses:

- 1. Restricted stock award will vest 100% on March 17, 2021.
- $2. This transaction \ represents \ shares \ withheld \ by \ the \ Company \ to \ cover \ the \ tax \ withholding \ obligations for \ the \ vesting \ of \ 6,000 \ shares \ during \ March \ 2017.$

## Remarks:

Martin E. Cearnal by /s/
Michael Bonner as attorney-infact

lact

\*\* Signature of Reporting Person Date

 $Reminder: Report \ on \ a \ separate \ line \ for \ each \ class \ of \ securities \ beneficially \ owned \ directly \ or \ indirectly.$ 

- $^{\star}$  If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- \*\* Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.